Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
Emma J GroenMarieke E M van der NoordaaMichael SchaapveldGabe S SonkeRitse M MannMette S van RamshorstEsther H LipsMarie-Jeanne T F D Vrancken PeetersFrederieke H van DuijnhovenJelle WesselingPublished in: Breast cancer research and treatment (2021)
As DCIS can respond to NST containing HER2-blockade, the presence of extensive DCIS in HER2-positive breast cancer before NST should not always indicate a mastectomy. The predictive factors we found could be helpful when considering breast-conserving surgery in these patients.
Keyphrases
- positive breast cancer
- end stage renal disease
- neoadjuvant chemotherapy
- minimally invasive
- newly diagnosed
- ejection fraction
- locally advanced
- chronic kidney disease
- rectal cancer
- lymph node
- prognostic factors
- peritoneal dialysis
- atrial fibrillation
- coronary artery disease
- combination therapy
- breast reconstruction
- smoking cessation
- replacement therapy